Apoptosis in patients with primary antiphospholipid antibody syndrome
Kuo-Tung Tang
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
Search for more papers by this authorTsu-Yi Hsieh
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
Search for more papers by this authorYa-Hsuan Chao
Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan
Search for more papers by this authorJu-Pi Li
Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorJoung-Liang Lan
Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
School of Medicine, China Medical University, Taichung, Taiwan
Search for more papers by this authorCorresponding Author
Chi-Chien Lin
Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Correspondence
Der-Yuan Chen, Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan.
Email: [email protected]
and
Chi-Chien Lin, Institute of Biomedical Sciences, College of Life Science, National Chung Hsing University, Taichung, Taiwan.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Der-Yuan Chen
Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
School of Medicine, China Medical University, Taichung, Taiwan
Correspondence
Der-Yuan Chen, Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan.
Email: [email protected]
and
Chi-Chien Lin, Institute of Biomedical Sciences, College of Life Science, National Chung Hsing University, Taichung, Taiwan.
Email: [email protected]
Search for more papers by this authorKuo-Tung Tang
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
Search for more papers by this authorTsu-Yi Hsieh
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
Search for more papers by this authorYa-Hsuan Chao
Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan
Search for more papers by this authorJu-Pi Li
Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
Search for more papers by this authorJoung-Liang Lan
Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
School of Medicine, China Medical University, Taichung, Taiwan
Search for more papers by this authorCorresponding Author
Chi-Chien Lin
Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Correspondence
Der-Yuan Chen, Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan.
Email: [email protected]
and
Chi-Chien Lin, Institute of Biomedical Sciences, College of Life Science, National Chung Hsing University, Taichung, Taiwan.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Der-Yuan Chen
Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
School of Medicine, China Medical University, Taichung, Taiwan
Correspondence
Der-Yuan Chen, Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan.
Email: [email protected]
and
Chi-Chien Lin, Institute of Biomedical Sciences, College of Life Science, National Chung Hsing University, Taichung, Taiwan.
Email: [email protected]
Search for more papers by this authorAbstract
Aim
Dysregulated apoptosis has been implicated in autoimmune diseases. In the present study, we investigated the apoptosis-related cytokines and apoptosis in patients with primary antiphospholipid syndrome (pAPS).
Method
We prospectively recruited 12 pAPS patients, 17 antiphospholipid antibody (APA)-positive systemic lupus erythematosus (SLE) patients without APS manifestations (APA+SLE), 13 SLE patients with secondary APS (APS+SLE) and 10 healthy controls (HCs). Plasma levels of soluble apoptosis-inducing ligands and cytokines, and the expression levels of apoptosis-inducing ligands in peripheral blood mononuclear cells, were determined. In addition, blood lymphocytes/monocytes apoptosis were determined in six pAPS patients and six HCs, using flow cytometric analysis of caspase 3, 8 and 9 activities.
Results
There was a trend toward higher plasma levels of soluble tumor necrosis factor (TNF)-related apoptosis-inducing ligand (sTRAIL), interleukin-10 (IL-10) and TNF-α in pAPS patients when compared with HCs. We also observed higher plasma levels of IL-10 and TNF α in APA+SLE and APS+SLE patients when compared with HCs. However, there was no significant difference in blood lymphocytes/monocytes apoptosis between pAPS patients and HCs.
Conclusion
There was a trend toward elevated plasma levels of sTRAIL, IL-10 and TNF-α, but no evidence for dysregulated apoptosis in pAPS patients.
REFERENCES
- 1Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nature Rev Mol Cell Biol. 2008; 9(3): 231-241.
- 2Silva MT. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett. 2010; 584(22): 4491-4499.
- 3Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365(22): 2110-2121.
- 4Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016; 12(10): 570-579.
- 5Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998; 41(7): 1241-1250.
- 6Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994; 152(7): 3685-3692.
- 7Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2(4): 277-288.
- 8Kaplan MJ, Lewis EE, Shelden EA, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol. 2002; 169(10): 6020-6029.
- 9Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013; 368(11): 1033-1044.
- 10Rauch J, Subang R, D'Agnillo P, Koh JS, Levine JS. Apoptosis and the antiphospholipid syndrome. J Autoimmun. 2000; 15(2): 231-235.
- 11Levine JS, Subang R, Koh JS, Rauch J. Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun. 1998; 11(5): 413-424.
- 12Tang KT, Hsieh TY, Chao YH, et al. Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. PLoS ONE. 2017; 12(5): e0178404.
- 13Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295-306.
- 14Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
- 15Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8): 2677-2686.
- 16Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003; 22(53): 8628-8633.
- 17Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC. TRAIL (Apo2 Ligand) and TWEAK (Apo3 Ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol. 2000; 164(6): 2897-2904.
- 18Matsumura R, Umemiya K, Kagami M, et al. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome. Clin Exp Rheumatol. 2002; 20(6): 791-798.
- 19Huang WX, Huang MP, Gomes MA, Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology. 2000; 55(7): 928-934.
- 20Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S, Via CS. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin Immunol. 2005; 117(1): 48-56.
- 21Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005; 64(6): 854-858.
- 22Rus V, Atamas SP, Shustova V, et al. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol. 2002; 102(3): 283-290.
- 23Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197(6): 711-723.
- 24Smadja D, Gaussem P, Roncal C, Fischer AM, Emmerich J, Darnige L. Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus. 2010; 19(7): 837-843.
- 25Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obsteter Gynecol. 2016; 214(1), 108. e1–e14.
- 26Di Bartolo BA, Cartland SP, Prado-Lourenco L, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes angiogenesis and ischemia-induced neovascularization via NADPH Oxidase 4 (NOX4) and nitric oxide-dependent mechanisms. J Am Heart Assoc. 2015; 4(11).
- 27Cartland SP, Genner SW, Zahoor A, Kavurma MM. Comparative evaluation of TRAIL, FGF-2 and VEGF-A-induced angiogenesis in vitro and in vivo. Int J Mol Sci. 2016; 17(12): 2025.
- 28Na HJ, Hwang JY, Lee KS, et al. TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Angiogenesis. 2014; 17(1): 179-194.
- 29Chen PL, Easton AS. Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem Biophys Res Commun. 2010; 391(1): 936-941.
- 30Simoncini S, Njock MS, Robert S, et al. TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. Circulation Res. 2009; 104(8): 943-951.
- 31Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5): 364-371.
- 32Weckerle CE, Mangale D, Franek BS, et al. Large-scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum. 2012; 64(9): 2947-2952.
- 33Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014; 73(6): 1176-1180.
- 34Swadzba J, Iwaniec T, Musial J. Increased level of tumor necrosis factor-alpha in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state. Rheumatol Int. 2011; 31(3): 307-313.
- 35Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007; 56(8): 2687-2697.
- 36van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol. 1999; 45(6): 695-703.
- 37Hajeer AH, Lazarus M, Turner D, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol. 1998; 27(2): 142-145.
- 38Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol. 2001; 166(6): 3915-3922.
- 39Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995; 4(5): 393-395.
- 40Cush JJ, Splawski JB, Thomas R, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1): 96-104.
- 41Soltesz P, Der H, Veres K, et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology. 2008; 47(11): 1628-1634.
- 42Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy RJ, Bell AL. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis. 1999; 58(5): 309-314.
- 43Richardson BC, Yung RL, Johnson KJ, Rowse PE, Lalwani ND. Monocyte apoptosis in patients with active lupus. Arthritis Rheum. 1996; 39(8): 1432-1434.
- 44Cheng W, Liu F, Wang Z, et al. Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia. PLoS ONE. 2015; 10(12): e0144015.
- 45Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum. 1997; 40(5): 927-935.
- 46Liu ST, Wang CR, Yin GD, et al. Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol. 2001; 19(1): 29-35.
Citing Literature
